Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.
IVA · Inventiva S.A. · Documents
$3.14
-0.31 (-8.99%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$750.78M
Shares
239.10M
Volume · Nov 20
3.02M
Avg daily vol (3M)
2.37M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Oct 6
Current report
6-K
Current report
Sep 28
Sep 28
Current report
6-K
Current report
Inventiva S.A. completed a June 2026 refinancing, drew €75.0 million, had €166.1 million in cash and cash equivalents at June 30, 2026, and completed NATiV3’s final patient visit, targeting topline results in the fourth quarter of 2026.
Sep 3
Sep 1
Jul 30
Jul 29
Jul 9
Jul 6
Jun 12
Jun 12
Jun 9
Jun 3
Jun 3
Jun 2
May 26
May 22
Apr 22
Apr 8
Annual report
20-F
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Revenue 4.48M EUR
▼ 51.3%
Diluted EPS -1.90 EUR
Mar 31
Mar 30
Feb 17
2025
Nov 28
Current report
6-K
Current report
Nov 24
Current report
6-K
Current report
Nov 17
Current report
6-K
Current report
Nov 13
Current report
6-K
Current report
Nov 7
Current report
6-K
Current report
Nov 6
Current report
6-K
Current report
Nov 6
Current report
6-K
Current report
Oct 30
Current report
6-K
Current report
Oct 20
Current report
6-K
Current report
Oct 14
Current report
6-K
Current report
Oct 14
Registration statement
F-3
Registration statement
Oct 1
Current report
6-K
Current report
Sep 29
Current report
6-K
Current report
Jul 29
Current report
6-K
Current report
Jul 9
Current report
6-K
Current report
Jul 7
Current report
6-K
Current report
May 23
Current report
6-K
Current report
May 23
Current report
6-K
Current report
May 22
Current report
6-K
Current report
May 5
Current report
6-K
Current report
May 2
Current report
6-K
Current report
Apr 30
Current report
6-K
Current report
Apr 30
Current report
6-K
Current report
Apr 24
Current report
6-K
Current report
Apr 15
Annual report
20-F
FY2024, ended Dec 31
Annual report for FY2024
Revenue 9.2M EUR
▼ 47.4%
Net loss 184.21M EUR
Diluted EPS -3.08 EUR
Apr 11
Current report
6-K
Current report
Apr 1
Current report
6-K
Current report
Mar 26
Current report
6-K
Current report
Showing 1–50 of 169 documents
Key facts
CIK
1756594
CUSIP
46124U107
13F (30d)
94 filings
93 filers
Visit website
Investor relations